Untitled

Abstract

Inflammatory bowel diseases (IBD) are chronic and relapsing intestinal inflammatory conditions, hallmarked by a disturbance in the bidirectional interaction between gut and brain. IBD is Ulcerative colitis (UC) and Crohn's disease (CD). Conventional therapies are inadequate and are associated with several systemic side effects due to lack to localization of active moiety at the inflamed site. Treatment option range from small molecules to macromolecules (peptides, proteins and oligonucleotides) that target multiple therapeutic pathways, and dosed via injectable, oral or the rectal route for local bowel treatment. Conventional therapies are inadequate and are associated with several systemic side effects due to a lack of localization of active moiety at the inflamed site. But colonic drug targeting is a novel, potentially active area of research intended and focused on drug delivery for treating localized disease. Targeted drug delivery to the colon would ensure direct treatment at the disease site, lower dosing, and fewer systemic side effects. INTRODUCTION:Inflammatory bowel disease (IBD) is a persistent intestinal inflammatory disease with an unknown etiology. IBD is composed of two specific disease entities: Crohn's disorder (CD) and ulcerative colitis (UC). IBD has been idea to be idiopathic however has two fundamental attributable causes that include genetic and environmental factors. The gastrointestinal tract in which this ailment takes place is imperative to the immune system, and the innate and adaptive immune systems are balanced in complicated interactions with intestinal microbes underneath homeostatic conditions 1 .